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Purpose: To investigate the involvement of stress-regulating genes, endothelial nitric oxide synthase (eNOS) and heat
shock protein 70 (HSP70) with primary open angle glaucoma (POAG) and primary closed angle glaucoma (PCAG).
Methods: POAG and PCAG patients recruited from different areas of Pakistan were diagnosed on the basis of clinical
history, raised intraocular pressure (IOP), cup-to-disc ratio (CDR) and visual field defects. Their blood was collected and
genomic DNA was extracted from it, followed by PCR amplification and VNTR typing of the eNOS gene, while the
HSP70 SNP was analyzed with PCR-RFLP. For both of the polymorphisms, the genotype distribution of the POAG and
PCAG patients was compared with unaffected controls.
Results: HSP70 polymorphism was found to be significantly associated with PCAG (χ2=15.29 [p<0.001], OR=2.63 [95%
CI=1.55–4.48]), with p<0.001 for the dominant model and OR=2.09 (95% CI=1.10–3.96) , with p<0.01 for the recessive
model, but not with POAG (χ2=2.96 [p>0.05]). As opposed to this significant eNOS association, was seen with PCAG
(χ2=6.33 [p<0.05], OR=2.09 [95% CI=1.12–3.89]), with p<0.01 for the dominant model, as well as with POAG (χ2=8.89
[p<0.05], OR=2.23 [95% CI=1.26–3.39]), with p<0.01 for dominant model. For the eNOS case, we found a significant
association with the risk allele “a” for POAG patients (χ2=9.29 [p<0.01], OR=2.02 [95% CI=1.25–3.28, p=0.001]) and
PCAG patients (χ2=7.59 [p<0.01], OR=1.99 [95% CI=1.18–3.37, p<0.01]). Similarly, in the HSP70 case, there was a
significant association with the risk allele “C” for POAG patients (χ2=3.57 [p=0.05], OR=1.38 [95% CI=0.97–1.94,
p<0.05]) and PCAG patients (χ2=18.32 (p<0.001), OR=2.16 [95% CI=1.49–3.13, p<0.001]).
Conclusions: The intron 4 polymorphism of eNOS is associated with POAG, as well as PCAG, while the G+190C
polymorphism in HSP70 is associated with PCAG, but not with POAG in the Pakistani population.
Glaucoma is a multifactorial optic neuropathy
characterized by apoptotic cell death of the retinal ganglion
cells (RGCs) in the optic disc or retinal nerve fiber [1]. This
irreversible retinal deterioration results in progressive visual
field loss along with decreased contrast and color sensitivity
[2]. Quigly et al. [3] have estimated that by the year 2010,
approximately 60.5 million individuals will be affected by this
disease, which causes bilateral blindness, and this number
may rise to 79.6 million by the year 2020. Glaucoma is
classified as a silent disease because patients usually do not
have any signs and symptoms until the end stage, when
considerable damage has been done to the eye [4,5]. Increased
intraocular pressure (IOP) is an established risk factor of the
disease, along with old age, race and refractive error [6]. In
addition to these factors, vascular [7], immunological [8] and
neurotoxic [9] factors are also believed to cause glaucoma.
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Wiggs et al. [10] point to genetics as an additional risk
factor for the disease. Different strategies used to understand
the genetic risk factors have helped to define the molecular
events responsible for some Mendelian forms of the disease.
In addition, some of the chromosomal locations of the genes
that are likely to be involved in common forms of glaucoma
have also been identified.
Galassi et al. [11] have shown that as a result of a variety
of physiologic stresses, a highly conserved mechanism of
gene regulation is activated. Stress or hypoxia in the tissues
stimulates increased synthesis of Nitric oxide (NO), which
results in an increased blood flow in the vessels of the tissue
that helps to overcome the stress. Although several isoforms
of nitric oxide synthase (NOS) have been reported in
abundance in almost all layers of the retina, the circulating NO
is synthesized solely in the vascular endothelium through the
action of the endothelial nitric oxide synthase (eNOS) on the
substrate L-arginine. Studies to identify the eNOS promoter
element have revealed that many cis- and trans-acting factors
together regulate the expression of the eNOS gene, and the
level of eNOS expression, in turn, corresponds directly to the
amount of NO in the blood [12]. Experiments have revealed
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that polymorphisms in the non-coding regions of eNOS may
alter eNOS expression and thus cause a decrease in NO
synthesis [13], which may predispose patients to
hypertension, vasospasm and atherosclerosis.
In the vascular endothelium, an increase in the synthesis
of NOS has been shown to be neuroprotective through the
promotion of vasodilation and blood flow in the ocular tissue
[11]. In contrast to previous models, which associated
neuroprotection with higher eNOS activity, it has been
observed that higher NO levels that correspond to an excess
eNOS expression have pathological relevance and could be
generally toxic. This pathogenicity model states that the
excess NO freely diffuses to adjacent neurons and combines
with O2- to form peroxynitrite anions (ONOO-), an extremely
potent toxin which can set cell-death programs into motion,
such as neuronal apoptosis [14]. An abundance of NOS has
been found in the optic nerve head vessels of primary
glaucoma patients, supporting the idea that the optic nerve
damage in glaucoma can be related to eNOS overexpression
[15].
In determining the risk factors associated with increased
eNOS expression, it has been recognized that beside the many
environmental and other physiologic factors, there is also a
significant genetic contribution. One of the genetic risk factors
that has been identified is the 27-bp variable number of
tandem repeat (VNTR) polymorphism present in intron 4 of
eNOS, which is thought to alter NO production and contribute
to vascular deregulation [16]. In addition, it has been shown
that vascular deregulation and abnormal IOP in POAG might
together be responsible for causing optic nerve damage, and
both of these factors cause a reduction in ocular perfusion
[11]. No study has been conducted to define the relationship
of the vascular deregulation and PCAG.
The mechanical stress resulting from elevated IOP,
ischemia, excessive excitatory amino acids and excessive
TNFα release increases stress in the optic nerve head [17].
Another mechanism elicited in response to stress is the
recruitment of specific cellular proteins called “heat shock
proteins” (HSPs), which have been shown to have a protective
function [18], as the synthesis of the HSPs is upregulated in
response to many forms of metabolic stress. These proteins
are molecular chaperones that function in the proper refolding
of the dysfunctional proteins and prevent protein aggregation,
a mechanism that could be critical to the survival of RGCs;
thus, a low expression of HSPs will abolish the defense
mechanism against heat shock and stress in general [18].
Several investigators have shown that anti-HSP antibodies,
through the induction of the apoptotic mechanism or the HSPs
themselves via the stimulation of an immune response, may
have pathogenic significance for patients with glaucomatous
optic neuropathy [19].
The present study was conducted to determine whether
HSP70 and eNOS polymorphisms were associated with
POAG and PCAG in the Pakistani population. We hope that
our results will contribute toward a better understanding of the
disease’s causative agents.
METHODS
This was a multicenter case-control study in which the patients
and controls were randomly selected from different hospitals
in the area. The participants included 166 unaffected controls,
159 POAG patients and 111 PCAG patients.
The patients were selected on the basis of their clinical
history, cup–to-disc ratio (CDR) evaluation, visual field
evaluation and elevated IOP, and categorized into POAG and
PCAG groups based on gonioscopic findings. In addition, to
rule out any ocular anomaly, the controls also underwent
applanation tonometery, slit lamp examination, CDR
measurement and visual field assessment. Blood samples
from all of the individuals were collected by venipuncture
after informed written consent was obtained, and genomic
DNA was extracted from these blood samples through a
conventional phenol chloroform method [20]. This study has
been approved by the Departmental Ethics Committee and
conforms to all of the norms of the Helsinki Declaration.
The 27-bp insertional VNTR in intron 4 of eNOS was
typed with the use of PCR amplification. The VNTR region
was amplified using the Gene amp® PCR system 2700 (ABI,
Foster City, CA), with the help of the forward primer 5′-AGG
CCC TAT GGT AGT GCC TTT-3′ and the reverse primer
5′TCT CTT AGT GCT GTG CTC AC-3′. Briefly, the protocol
consisted of 35 cycles of DNA denaturation at 95°C for 1 min,
primer annealing at 60°C for 45 s and chain extension at 72°C
for 1 min, followed by a final extension cycle at 72°C for 5
min. The constituents of the reaction consisted of: 1.2 µM of
each primer, 10 mM of dNTPs, 2 mM of MgCl2, 1 U of Taq
and 1× PCR buffer, along with 40–50 ng of DNA. The PCR
products were electrophoresed on 4% agarose gels for 1 h and
the bands were visualized under ultraviolet light (Figure 1).
Two alleles were obtained when this region was amplified:
“eNOS4a,” which was 393 bp long and consisted of four 27-
bp repeating units, and “eNOS4b,” which was 420 bp long
and consisted of five 27-bp repeating units.
A 488-bp fragment encompassing the HSP70
polymorphism (rs1043618) was PCR-amplified by using the
forward and reverse primers, 5′-CGC CAT GGA GAC CAA
CAC CC-3′and 5′-GCG GTT CCC TGC TCT CTG TC-3′,
respectively. Each of the 35 cycles consisted of a DNA
denaturation step at 95°C for 1 min followed by primer
annealing at 60°C for 45 s and chain extension at 72°C for 1
min. The concentration of both primers was 0.04 µM, and the
reaction mixture also contained 0.2 mM dNTPs, 1.5 mM
MgCl2, 1 U Taq, 1× PCR buffer, and approx 90–100 ng of
DNA. The PCR-amplified products (17 µl) were then digested
overnight with BrsB1, as recommended by the manufacturer
(Fermentas, Burlington, Ontario). After digestion, the
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restriction enzyme was inactivated at 65°C for 20 min, and the
digestion products were electrophoretically separated on 4%
agarose gel for 2 h and visualized under UV transillumination
(Figure 2). The wild-type G allele was recognized based on
the presence of a single BrsB1 restriction enzyme recognition
site that, after digestion, yielded a 461-bp and a 27-bp
fragment, while the C allele that lacks the restriction site
remained uncut.
Genotype and allele frequencies in the unaffected
controls and the patients (POAG and PCAG) were compared
with the Pearson χ2 test. All of the data were analyzed by using
SPSS (ver. 16; SPSS, Chicago, Il). The statistically significant
differences were further analyzed using the statistical
software Minitab (ver.15; Minitab, Chicago, Il). A p value of
less than 0.05 was considered statistically significant.
RESULTS
Patients with POAG and PCAG and the controls were
genotyped for the eNOS4a/b and HSP70 G+190C
polymorphisms. In the controls, the frequencies of the
eNOS4b/b, eNOS4b/a and eNOS4a/a were 83.7%, 12.7%, and
3.6%, respectively, whereas in the POAG group, these values
were 70%, 24% and 6%, respectively, showing a significant
association of the disease with the polymorphism (χ2=8.89,
p<0.05). In the PCAG group, 71%, 22% and 7%, respectively,
were also found to be significantly associated with the disease
phenotype (χ2=6.33, p<0.05; Table 1). The eNOS4b/a
genotype was found to be significantly associated with POAG
(χ2=6.92 [p<0.01]), as well as with PCAG (χ2=3.93 [p<0.05]).
As opposed to this finding, the eNOS4b/b genotype was found
Figure 1. Amplification product of the 27-bp insertional variable
number of tandem repeat polymorphism in intron 4 of eNOS. The
amplified products were separated by electrophoresis on 4% agarose
gel. Lane L, 100-bp DNA ladder; lane NC, negative control (no
template DNA); lane PC, positive control; lane 1, 2 and 5,
homozygous eNOSb/b genotype (420 bp fragment); lane 3,
heterozygous, eNOSa/b genotype (420-bp and 393-bp fragments);
and lane 4, homozygous a/a genotype (393-bp fragment).
to be at a significantly higher frequency in the control samples
when compared with the POAG group (χ2=8.87, p<0.01) or
the PCAG group (χ2=6.26, p=0.01; Table 1). In addition to the
genotype associations, the eNOS4a allele frequency was
found to be significantly associated with both POAG
([χ2=9.29, p<0.01], OR=2.02 [95%CI=1.25–3.28, p=0.001])
and PCAG ([χ2=7.59, p<0.01], OR=1.99 [95%CI=1.18–3.37,
p<0.01]; Table 1).
The univariate logistic regression analysis revealed that
the eNOS4a/b polymorphism was significantly associated
with glaucoma (both POAG and PCAG), based on the
dominant model of inheritance (for POAG, OR=2.23 [95%
CI=1.26–3.39, p<0.01] and for PCAG, OR=2.09 [95%
CI=1.12–3.89, p<0.01]), but not according to the recessive
model (for POAG, OR=1.79 [95% CI=0.58–5.69, p>0.05] and
for PCAG, OR=1.16 [95%CI=0.40–3.31, p>0.05]; Table 1).
To study the association of HSP70 polymorphism G
+190C with glaucoma, the POAG and PCAG patients, as well
as the control samples, were genotyped. In the control group,
the frequency of GG, GC and CC genotypes was 58%, 27%
and 15%, respectively. For POAG patients, this distribution
was 48%, 32% and 20%, respectively, with no significant
association found for the genotype distribution in the patients,
as compared to the controls (χ2=2.96, p>0.05). In PCAG
patients, the frequency of the GG, GC and CC genotypes were
34%, 39% and 27%, respectively, and the genotype
distribution was found to be significantly associated with the
disease (χ2=15.29, p<0.001). The genotype CC was found to
be significantly associated with PCAG (χ2=5.26, p=0.01), but
not with POAG (χ2=1.12, p>0.05). In addition to the genotype
Figure 2. BrsB1 restriction enzyme-digested, PCR-amplified
product of HSP70 G+190C polymorphism (rs1043618). The
digested products were separated by electrophoresis on 4% agarose
gel. Lane L, 100-bp DNA ladder; lanes 1, 2 and 4, homozygous wild-
type G allele (461 bp and 27 bp [not shown]); and lane 3 and 5,
homozygous C risk allele (488 bp).
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distribution, the frequency of the G allele was found to be at
a significantly lower frequency in both patient groups
compared to in the control group, whereas the frequency of
the C allele was high in the POAG (χ2=3.57, p=0.05, OR=1.38
[95% CI=0.97–1.94, p<0.05]) and PCAG groups (χ2=18.32,
p<0.001, OR=2.16 [95% CI=1.49–3.13, p<0.001]; Table 2).
Univariate analysis of the HSP70 G+190C
polymorphism revealed that the polymorphism was not
associated with POAG when the data was analyzed according
to a dominant model (OR=1.44 [95% CI=0.91–2.29, p>0.05])
or a recessive model (OR=1.37 [95% CI=0.74–2.54,
p>0.05]). However, an analysis of PCAG revealed the data to
be significantly associated based on both the dominant
(OR=2.63 [95% CI=1.55–4.48, p<0.001]) and recessive
models (OR=2.09 [95% CI=1.10–3.96, p<0.01]).
DISCUSSION
Glaucoma is a disease leading to optic neuropathy and the
second leading cause of blindness in the world. The slow,
progressive loss of the retinal nerve ganglion cells in
glaucoma results in peripheral vision loss. Glaucoma is a
multifactorial disease and its exact etiology is still unknown.
It has been reported that both genetic and environmental
factors are significant in the progression of the disease. A
multitude of recent genetic linkage studies have led to the
identification of genetic loci, while genome wide search
techniques have been used to identify single nucleotide
polymorphisms, which have been observed to be associated
with the disease.
In the present study, we provide data on two different
polymorphisms of two genes, the 27-bp repeat eNOS VNTR
polymorphism and the HSP70 G+190C polymorphism. The
eNOS and HSP70 genes have been shown to elicit enhanced
transcription levels of the respective mRNA when the body is
under stress [18,21].
eNOS is involved in different processes, like
neurotransmission, the regulation of vascular tone,
vasodilatation and apoptosis. In addition, it also regulates
blood flow to the ocular tissues and has been implicated in the
pathogenesis of cardiovascular diseases and different
neurodegenerative disorders, like diabetic retinopathy [22],
glaucoma [23] and migraines [24]. In focusing on glaucoma,
Liu and Neufeld [21] demonstrated that RGC degeneration in
the glaucomatous optic nerve head of POAG patients clearly
corresponds to excess plasma NO-mediated neurotoxicity.
However, the authors did not conduct any genetic studies to
find the susceptible loci.
TABLE 1. GENOTYPE AND ALLELE FREQUENCIES OF INTRON 4 POLYMORPHISM OF ENOS IN CONTROLS AND PATIENTS.
Genotype Controls
(n=166)
POAG
(n=159)
p (χ2) p (χ2) Odds ratio (95% CI) PCAG
(n=111)
p (χ2) p (χ2) Odds ratio (95% CI)
b/b 139 (83.7%) 111
(70%)
<0.05
(8.89)
<0.01
(8.87)
DM=2.23 (1.26–3.39)
p<0.01
79 (71%) <0.05
(6.33)
0.01
(6.26)
DM=2.09 (1.12–3.89)
p<0.01
b/a 21 (12.7%) 38 (24%) <0.01
(6.92)
 24 (22%) <0.05
(3.93)
 
a/a 6 (3.6%) 10 (6%) >0.05
(1.24)
RM=1.79 (0.58–5.69)
p>0.05
8 (7%) >0.05
(1.79)
RM=1.16 (0.40–3.31)
p>0.05
Allele Controls POAG p (χ2)  Odds ratio (95% CI) PCAG p (χ2)  Odds ratio (95% CI)
b 299 (90%) 260
(82%)
<0.01
(9.29)
 2.02 (1.25–3.28)
p=0.001
182
(82%)
<0.01
(7.59)
 1.99 (1.18–3.37)
p<0.01
a 33 (10%) 58 (18%)   40 (18%)  
DM=dominant model, RM=recessive model
TABLE 2. GENOTYPE AND ALLELE FREQUENCIES OF G+190C POLYMORPHISM OF HSP70 IN CONTROLS AND PATIENTS.
Genotype Controls
(n=166)
POAG
(n=159)
p (χ2) p (χ2) Odds ratio (95% CI) PCAG
(n=111)
p (χ2) p (χ2) Odds ratio (95% CI)
G/G 96 (58%) 77 (48%) >0.05
(2.96)
>0.05
(2.88)
DM=1.44 (0.91–2.29)
p>0.05
38 (34%) <0.001
(15.29)
<0.001
(14.38)
DM=2.63 (1.55–4.48)
p<0.001
G/C 45 (27%) 51 (32%) >0.05
(0.96)
 43 (39%) <0.05
(4.15)
 
C/C 25 (15%) 31 (20%) >0.05
(1.12)
RM=1.37 (0.74–2.54)
p>0.05
30 (27%) 0.01
(5.26)
RM=2.09 (1.10–3.96)
p<0.01
Allele Controls POAG p (χ2)  Odds ratio (95% CI) PCAG p (χ2)  Odds ratio (95% CI)
G 237 (71%) 205
(64%)
0.05
(3.57)
 1.38 (0.97–1.94)
p<0.05
119
(54%)
<0.001
(18.32)
 2.16 (1.49–3.13)
p<0.001
C 95 (29%) 113
(36%)
 103 (46%)  
DM=dominant model, RM=recessive model
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Plasma NO levels are regulated by eNOS, thus any
environmental or genetic risk factor that enhances eNOS
expression would contribute to NO mediated toxicity. It has
been established that the VNTR in the intron 4 of eNOS
significantly influences the plasma NO levels. Functional
studies have shown that the variant a allele (with four 27-bp
repeats) in homozygous form is strongly correlated with
increased plasma NO levels, which were twice as high as the
level found in the b/b genotype (with five 27-bp repeats),
indicating the eNOS’ underlying potential for excess NO-
related pathogenicity [25].
It was hypothesized that the molecular mechanism of
eNOS expression was regulated at the transcriptional levels
by microRNAs, which can be derived from the intron during
pre-mRNA splicing [26]. Based on this hypothesis, Zhang et
al. [27] conducted experiments and established the role of
intron 4 VNTR repeat with eNOS expression by identifying a
27-nucleotide microRNA sequence derived from the 27-
nucleotide repeat within intron 4 of eNOS. This microRNA
was shown to represses eNOS expression by interfering with
the gene transcription efficiency. In addition, they
demonstrated that this microRNA acted as an endogenous
sequence-specific feedback regulatory molecule that
reversibly inhibited this process and thus enabled the rapid
turnover of eNOS molecules to minimize the damage
associated with stress and hypoxia. The presence of the
endogenous expression of the microRNA from intronic
sequences was further demonstrated by the unexpected
finding that the 5′ and 3′ ends of the 27-nucleotide repeat unit
in intron 4 of eNOS had splice donor and acceptor sites (AG
and GA) similar to the 5′ and 3′ bases at the exonic ends in the
eNOS genomic sequence. This further supported the
hypothesis that the intact microRNAs are produced when pre-
mRNA splicing of eNOS occurs and that the amount of
microRNA is determined by the number of repeats in intron
4 [27].
Zang et al. [27] also postulated that the amount of
microRNA would vary from individual to individual,
depending on the number of repeats at this position, which
would account for the variations observed between the
individuals and their expression of eNOS and its association
with cardiovascular risk. Consequently, compared to the b
allele with five 27-bp repeats, variant a allele with 4 repeats
produced fewer microRNAs and hence, reduced
transcriptional repression would occur, correlating with the
increased plasma NO. Our current results are in line with the
above results, as we found a significant association of the
eNOS4 a/b genotype with both forms of glaucoma in the
Pakistani groups, which is probably a result of high plasma
NO levels that are toxic to the optic nerve and ultimately cause
its degeneration, a classic hallmark of glaucoma. Earlier
studies conducted to establish a possible association between
glaucoma and altered NOS expression focused mainly on
POAG patients [11,12] and were able to show a positive
correlation between this polymorphism and the disease,
matching our results.
In the current work, we also studied PCAG as an
impairment in the ocular blood flow that might lead to closure
of the angle, which can be partially associated with altered
eNOS expression and the resultant NO-mediated
neurotoxicity. Our results indicate that there is indeed a
correlation between PCAG and the polymorphism in the
eNOS gene, as we found a significantly higher frequency of
the variant eNOS4a allele in PCAG patients compared to the
controls. Thus, in the Pakistani PCAG and POAG groups, the
disease could be associated with increased NOS activity.
Our findings are consistent with the results of Sakai et al.
[28], who found the T(−786)C polymorphism of eNOS to be
a risk factor in patients developing non-arteritic anterior
ischemic optic neuropathy (NAION) disease [28]. However,
while studying glaucoma, Logan et al. [13] were unable to
show a significant association between eNOS polymorphism
T786C and VNTR repeat polymorphism and the disease.
Similarly, Sena et al. [29] and Lin et al. [30] did not find any
association between POAG and eNOS intron 4 VNTR. As
opposed to this finding, however, Colombo et al. [31] have
shown an association between Glu289Asp and T788C
polymorphism of eNOS and cardiac myopathies, wherein
patients who carried both polymorphisms had a higher risk of
developing the disease. Polak et al. [32] studied the role of the
NO system in glaucoma patients by giving POAG patients and
normal healthy controls NG-monomethyl-L-arginine, which
is an NOS inhibitor. They observed that glaucoma patients did
not respond to the drug due to abnormal NOS activity, whereas
healthy controls showed reduced choroidal and optic nerve
head blood flow [32].
NO is responsible for maintaining arteries’ vasodilation,
which keeps the ocular blood flow constant. When the
endothelial function is deregulated, the blood supply to the
tissue is altered and impaired blood flow damages the optic
nerve and leads to the development of glaucomatous changes
in the optic nerve, which then results in an increase in the
CDR. In our study group, an increased CDR, as compared to
the controls (C/D=0.29±0.11), was observed in the POAG
group (C/D=0.75±0.24, p<0.001), as well as in the PCAG
group (C/D=0.67±0.28, p<0.001). This increased CDR in
both patient groups is evidence of excessive optic nerve
damage, possibly as a result of NO activity. In addition to the
differences in the CDR between the controls and the two
patient groups, the POAG patients had a significantly higher
CDR compared to the PCAG patients (p<0.001).
It has been suggested that the HSPs are involved in the
defense mechanism of stress-mediated neuron injury, caused
by an increased IOP in glaucoma patients. In addition, these
proteins recruit antigen presenting cells, thus they also act as
immune stimulatory molecules. Therefore, in addition to their
neuroprotective function, when they are overexpressed in the
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cell, they potentially contribute to disease progression by
activating the autostimulatory response that leads to optic
nerve neuropathy [17,18]. This is supported by the
observation that in glaucoma patients, increased titers of anti-
HSP antibodies are present, which facilitate the disease’s
progression by diminishing the protective abilities of the
native HSPs [33].
This tight regulation of the HSPs’ expression pattern
determines the fate of the cell, where underexpression leads
to an inefficient stress response and overexpression drives the
immunodestruction, with the outcome in both cases being
destruction —— driven by the oxidative free radicals in one
case and by cytokines in the other, respectively. This is
supported by a study conducted by Tezel et al. [33], who have
previously shown HSPs to be significant enhancers of both
the cytoprotective and neurodegenerative functions of the
immune system in RGCs and glial cells, and clearly
demonstrated that these proteins were critical in facilitating
the glaucomatous changes caused by optic nerve damage and
neurodegeneration [33]. Because optic nerve neuropathy in
glaucoma is the major cause of blindness in Pakistan, we were
therefore interested in studying the possible association
between the HSP70 polymorphism and POAG and PCAG in
the Pakistani population.
Our specific interest was to study the stress-mediated
responses and their association with glaucoma. We thus chose
the G+190C polymorphism for genotypic studies, as this
polymorphism has previously been shown to be associated
with reduced HSP70 expression, which could represent an
inability to cope with cellular stress and perform
cytoprotective functions. Functional analyses of the G+190C
polymorphism, which maps to the 5′ UTR region of HSP70,
have revealed that compared with the G allele, the variant C
allele causes reduced promoter activity and lower HSP70
protein levels [34]. Tosaka et al. [19] had previously reported
a significant association between the A-110C polymorphism
of HSP70–1 and POAG (p=0.026) in the Japanese population;
this polymorphism is known to increase HSP70 expression,
thus supporting the hypothesis that neuropathy is associated
with autoimmunity. However, Tosaka et al. [19] did not find
any association between glaucoma and the G+190C
polymorphism, which supports the alternate model of
pathogenicity related to HSP70 cytoprotective functions. As
in the Japanese population, we also did not observe any
association between the G+190C polymorphism and POAG,
but we did find a highly significant association between the
polymorphism and PCAG in the Pakistani study group.
One possible manner in which eNOS and HSPs might
contribute to PCAG is by affecting the expression of matrix
metalloproteinases (MMPs). MMPs have been found to be
involved in the regulation of IOP and might play a significant
role in the normal and pathogenic functions of the eye [35].
The malfunction of the MMP9 protein has previously been
shown to be associated with PCAG [36]. The NOS gene plays
an important role in controlling the activity of MMPs in flow-
induced remodeling [37] and hence, the polymorphism we
studied could potentially be associated with the overactivation
of MMPs, which could then possibly result in PCAG. Other
lines of evidence have also suggested a role for HSP70 in the
expression of the MMP9 gene [38]. It must be pointed out that
to fully understand the role of HSPs in the regulation of
MMPs, it is important to conduct further expression and
activity assays.
In conclusion, glaucoma is a heterogeneous disorder with
different environmental and genetic factors driving the
etiology of the disease. Various polymorphisms have been
reported to be associated with this disease in different
populations. Our study represents a step forward in terms of
clarifying the role of the stress-related cellular components
eNOS and HSP70 and their role in causing glaucoma,
particularly in regard to Pakistani patients, and in terms of
contributing to the current body of knowledge. There is a
further need to conduct studies in different populations across
the world to fully unravel the genetic basis of glaucoma, which
will ultimately lead to a better understanding of the disease’s
underlying mechanisms. Once the disease’s mechanisms are
completely understood, better therapeutic interventions can
be devised.
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